Cumulative, additive benefits of memantine-donepezil combination over component monotherapies in moderate to severe Alzheimer’s dementia: a pooled area under the curve analysis

INTRODUCTION: Treatment in moderate or severe Alzheimer’s disease (AD) often involves adding memantine to a cholinesterase-inhibitor (ChEI: donepezil, galantamine, rivastigmine). Evidence from six-month randomized trials and long-term observational studies supports superiority of memantine-ChEI comb...

Descripción completa

Detalles Bibliográficos
Autores principales: Atri, Alireza, Hendrix, Suzanne B, Pejović, Vojislav, Hofbauer, Robert K, Edwards, John, Molinuevo, José Luis, Graham, Stephen M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4436119/
https://www.ncbi.nlm.nih.gov/pubmed/25991927
http://dx.doi.org/10.1186/s13195-015-0109-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4436119/
https://www.ncbi.nlm.nih.gov/pubmed/25991927
http://dx.doi.org/10.1186/s13195-015-0109-2

Ejemplares similares